Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024 2024-12-10 08:30
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country 2024-11-28 13:04
Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting 2024-11-06 09:08
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 2024-11-06 08:30
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country 2024-10-18 10:35
Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting 2024-10-07 13:14
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand 2024-09-23 17:42
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024 2024-09-16 18:00
Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization 2024-08-23 12:32
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia 2024-08-06 08:00
Antennova Announces CD73 Small Molecule Inhibitor Accepted for Mini Oral Presentation at ESMO Congress 2024 2024-08-05 20:00
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country 2024-07-05 21:18
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea 2024-06-26 16:44
Antengene To Present One Oral and Four Abstracts at ASCO 2024 2024-05-24 08:30
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024 2024-04-25 20:00
Antengene Presents Four Preclinical Posters at AACR 2024 2024-04-06 08:30
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline 2024-03-22 18:00
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia 2024-03-20 20:30
Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research 2024-03-20 08:30
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms 2024-03-06 08:30
1 2 3 4 5 8